TD Cowen Lifts Natera (NTRA) Target to $240, Reiterates Buy Rating
Natera, Inc. (NASDAQ:NTRA) is one of the best gene-editing stocks to buy according to hedge funds. On November 7, Daniel Brennan, an analyst at TD Cowen, reiterated a Buy rating on Natera, Inc.





